Although several monoclonal antibodies (mAbs) targeting severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 …

The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …

Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Dear Editor, The ongoing COVID-19 pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in unprecedented public health and …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …

One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …

Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued …

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …

Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain
(RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …